M
Micki Nelson
Researcher at Merck & Co.
Publications - 7
Citations - 2688
Micki Nelson is an academic researcher from Merck & Co.. The author has contributed to research in topics: Vaccination & Rotavirus vaccine. The author has an hindex of 7, co-authored 7 publications receiving 2550 citations. Previous affiliations of Micki Nelson include United States Military Academy.
Papers
More filters
Journal ArticleDOI
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
Suzanne M. Garland,Suzanne M. Garland,Mauricio Hernández-Ávila,Cosette M. Wheeler,Gonzalo Perez,Diane M. Harper,Sepp Leodolter,Grace W.K. Tang,Daron G. Ferris,Marc Steben,Janine T. Bryan,Frank J. Taddeo,Radha Railkar,Mark T. Esser,Heather L. Sings,Micki Nelson,John W. Boslego,Carlos Sattler,Eliav Barr,Laura A. Koutsky +19 more
TL;DR: The quadrivalent vaccine significantly reduced the incidence of HPV-associated anogenital diseases in young women in this randomized, placebo-controlled, doubleblind trial.
Journal ArticleDOI
Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials
Elmar A. Joura,Sepp Leodolter,Mauricio Hernández-Ávila,Cosette M. Wheeler,Gonzalo Perez,Laura A. Koutsky,Suzanne M. Garland,Diane M. Harper,Grace W.K. Tang,Daron G. Ferris,Marc Steben,Ronald W. Jones,Janine T. Bryan,Frank J. Taddeo,Oliver M Bautista,Mark T. Esser,Heather L. Sings,Micki Nelson,John W. Boslego,Carlos Sattler,Eliav Barr,Jorma Paavonen +21 more
TL;DR: Prophylactic administration of quadrivalent HPV vaccine was effective in preventing high-grade vulval and vaginal lesions associated with HPV16 or HPV18 infection in women who were naive to these types before vaccination.
Journal ArticleDOI
Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection
Luisa L. Villa,Gonzalo Perez,Susanne K. Kjaer,Jorma Paavonen,Matti Lehtinen,Nubia Muñoz,Kristjan Sigurdsson,Mauricio Hernández-Ávila,Ole Eric Iversen,Steinar Thoresen,Patricia J. Garcia,Slawomir Majewski,Hseon Tay Eng,F. Xavier Bosch,Joakim Dillner,Sven Eric Olsson,Kevin A. Ault,Darron R. Brown,Daron G. Ferris,Laura A. Koutsky,Robert J. Kurman,Evan R. Myers,Eliav Barr,John W. Boslego,Janine T. Bryan,Mark T. Esser,Teresa M. Hesley,Micki Nelson,Radha Railkar,Margaret James,Carlos Sattler,Frank J. Taddeo,Annemarie R. Thornton,Scott Vuocolo +33 more
TL;DR: In this article, the quadrivalent human papillomavirus (HPV) L1 virus-like-particle (VLP) vaccine has been shown to be 95%-100% effective in preventing cervical and genital disease related to HPV-6, 11, 16, and 18 in 16-26-year-old women naive for HPV vaccine types.
Journal ArticleDOI
Noninferiority of Antibody Response to Human Papillomavirus Type 16 in Subjects Vaccinated with Monovalent and Quadrivalent L1 Virus-Like Particle Vaccines
Suzanne M. Garland,Marc Steben,Mauricio Hernández-Ávila,Laura A. Koutsky,Cosette M. Wheeler,Gonzalo Perez,Diane M. Harper,Sepp Leodolter,Grace W.K. Tang,Daron G. Ferris,Mark T. Esser,Scott Vuocolo,Micki Nelson,Radha Railkar,Carlos Sattler,Eliav Barr +15 more
TL;DR: A study to evaluate anti-HPV16 responses among subjects receiving three-dose regimens of either a monovalent HPV16 vaccine or a quadrivalent HPV (types 6, 11, 16, and 18) vaccine.
Journal ArticleDOI
Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: A randomized, double-blind, placebo-controlled trial.
Zhaojun Mo,Yi Mo,Ming-Qiang Li,Junhui Tao,Xu Yang,Jilian Kong,Dingkai Wei,Botao Fu,Xueyan Liao,Jianli Chu,Yuanzheng Qiu,Darcy A. Hille,Micki Nelson,Susan S. Kaplan +13 more
TL;DR: In Chinese infants, RV5 was efficacious against any-severity and severe RVGE caused by any serotype and generally well-tolerated with respect to AEs.